000179951 001__ 179951
000179951 005__ 20240229145600.0
000179951 0247_ $$2doi$$a10.1093/noajnl/vdac026
000179951 0247_ $$2pmid$$apmid:35475274
000179951 0247_ $$2pmc$$apmc:PMC9034118
000179951 0247_ $$2altmetric$$aaltmetric:124608296
000179951 037__ $$aDKFZ-2022-01000
000179951 041__ $$aEnglish
000179951 082__ $$a610
000179951 1001_ $$0P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5$$aKrausert, Sonja$$b0$$eFirst author
000179951 245__ $$aPredictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma.
000179951 260__ $$aOxford$$bOxford University Press$$c2022
000179951 3367_ $$2DRIVER$$aarticle
000179951 3367_ $$2DataCite$$aOutput Types/Journal article
000179951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677657915_27753
000179951 3367_ $$2BibTeX$$aARTICLE
000179951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179951 3367_ $$00$$2EndNote$$aJournal Article
000179951 500__ $$a#EA:B062#LA:B062# / 2022 Mar 13;4(1):vdac026
000179951 520__ $$aInhibition of the sonic hedgehog (SHH) pathway with Smoothened (SMO) inhibitors is a promising treatment strategy in SHH-activated medulloblastoma, especially in adult patients. However, the problem is that tumors frequently acquire resistance to the treatment. To understand the underlying resistance mechanisms and to find ways to overcome the resistance, preclinical models that became resistant to SMO inhibition are needed.To induce SMO inhibitor resistant tumors, we have treated a patient-derived xenograft (PDX) model of SHH medulloblastoma, sensitive to SMO inhibition, with 20 mg/kg Sonidegib using an intermitted treatment schedule. Vehicle-treated and resistant models were subjected to whole-genome and RNA sequencing for molecular characterization and target engagement. In vitro drug screens (76 drugs) were performed using Sonidegib-sensitive and -resistant lines to find other drugs to target the resistant lines. One of the top hits was then validated in vivo.Nine independent Sonidegib-resistant PDX lines were generated. Molecular characterization of the resistant models showed that eight models developed missense mutations in SMO and one gained an inactivating point mutation in MEGF8, which acts downstream of SMO as a repressor in the SHH pathway. The in vitro drug screen with Sonidegib-sensitive and -resistant lines identified good efficacy for Selinexor in the resistant line. Indeed, in vivo treatment with Selinexor revealed that it is more effective in resistant than in sensitive models.We report the first human SMO inhibitor resistant medulloblastoma PDX models, which can be used for further preclinical experiments to develop the best strategies to overcome the resistance to SMO inhibitors in patients.
000179951 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000179951 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179951 650_7 $$2Other$$aSHH Medulloblastoma
000179951 650_7 $$2Other$$aSMO inhibitor
000179951 650_7 $$2Other$$aSelinexor
000179951 650_7 $$2Other$$aSonidegib
000179951 650_7 $$2Other$$aresistance
000179951 7001_ $$0P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aBrabetz, Sebastian$$b1$$eFirst author
000179951 7001_ $$0P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aMack, Norman L$$b2
000179951 7001_ $$0P:(DE-He78)fce464e68d8888e5e7be72b7a197bca7$$aSchmitt-Hoffner, Felix$$b3
000179951 7001_ $$0P:(DE-He78)9ce969bf1ac7913b3f2b1cf4dd7f823e$$aSchwalm, Benjamin$$b4
000179951 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b5
000179951 7001_ $$0P:(DE-He78)6e122c2e77e540ca21733dea44551034$$aMangang, Aileen$$b6
000179951 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b7
000179951 7001_ $$0P:(DE-He78)a4101d4d75f0b7d1f24f67ccbe63164b$$aSieber, Laura$$b8
000179951 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b9
000179951 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b10
000179951 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b11
000179951 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b12
000179951 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b13
000179951 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b14$$eLast author
000179951 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdac026$$gVol. 4, no. 1, p. vdac026$$n1$$pvdac026$$tNeuro-oncology advances$$v4$$x2632-2498$$y2022
000179951 909CO $$ooai:inrepo02.dkfz.de:179951$$pVDB
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fce464e68d8888e5e7be72b7a197bca7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9ce969bf1ac7913b3f2b1cf4dd7f823e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e122c2e77e540ca21733dea44551034$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a4101d4d75f0b7d1f24f67ccbe63164b$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000179951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000179951 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000179951 9141_ $$y2022
000179951 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2020-09-05
000179951 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000179951 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000179951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000179951 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-23T13:25:59Z
000179951 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-23T13:25:59Z
000179951 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-09-23T13:25:59Z
000179951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000179951 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2022-11-12
000179951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000179951 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000179951 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000179951 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000179951 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x2
000179951 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000179951 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x4
000179951 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000179951 980__ $$ajournal
000179951 980__ $$aVDB
000179951 980__ $$aI:(DE-He78)B062-20160331
000179951 980__ $$aI:(DE-He78)HD01-20160331
000179951 980__ $$aI:(DE-He78)B310-20160331
000179951 980__ $$aI:(DE-He78)C060-20160331
000179951 980__ $$aI:(DE-He78)B300-20160331
000179951 980__ $$aUNRESTRICTED